A new medication for adults with certain types of soft tissue sarcoma who can’t be cured with radiation or surgery has received FDA approval for use with the chemotherapy drug doxorubicin.
“This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin’s approval more than 40 years ago,” Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement.
Voelker R. Progress for Soft Tissue Sarcoma . JAMA. 2016;316(23):2474. doi:10.1001/jama.2016.17232